Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AWARD-6: Once-weekly dulaglutide vs once-daily liraglutide in type 2 diabetes
2011-003810-18Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2012
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dulaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in HbA1c from baseline to 26 weeks (primary endpoint). Started May 2012; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-003810-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003810-18.